Current and future intratumoral targeted treatment for pancreatic cancer. (August 2014)

• Record Type: Journal Article
• Authors: Zarogoulidis, Paul; Pavlioglou, Paschalis; Pivert, Patrick Le; Machairiotis, Nikolaos; Katsikogiannis, Nikolaos; Kougioumtzi, Ioanna; Tsimogiannis, Konstantinos; Kakolyris, Stylianos; Courcoutsakis, Nikolaos; Tsiouda, Theodora; Sakkas, Antonios; Makrantonaki, Dimitra; Zarogoulidis, Konstantinos
• Is Part Of: Therapeutic delivery. Volume 5:Number 8(2014)
• Page Start: 913
• Page End: 926
• Publication Date: 2014-08
• Subjects: Drug delivery systems -- Periodicals; Therapeutics -- Periodicals; 615.6
• DOI: 10.4155/tde.14.44
• Languages: English
• ISSNs: 2041-5990

Abstract

Pancreatic cancer is an insidious type of cancer with its symptoms manifested upon extensive disease. The overall 5-year survival rates between 0.4 and 4%. Surgical resection is an option for only 10% of the patients with pancreatic cancer. Local recurrence and hepatic metastases occur within 2 years after surgery. There are currently several molecular pathways investigated and novel targeted treatments are on the market. However; the nature of pancreatic cancer with its ability to spread locally in the primary site and lymph nodes indicates that further experimentation with local interventional therapies could be a future treatment proposal as palliative care or adjunct to gene therapy and chemotherapy/radiotherapy. In the current review, we will summarize the molecular pathways and present the interventional treatment options for pancreatic cancer.